For the first time in more than a decade, a new frontline treatment for an incurable blood cancer is being added to the ...

Vilastobart in combination with atezolizumab continued to demonstrate a differentiated and generally well-tolerated safety profile. Treatment-related adverse events (AEs) were primarily Grade 1 or 2, ...

The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's drug to treat a ...

Multiple myeloma is a cancer that develops in bone marrow plasma cells, crowding out healthy blood cells and damaging the bones.

Link to the article in Clinical Cancer Research.] The study utilized Droplet's LymphDetect (TM) liquid biopsy assay for HPV-independent head & neck cancer. Results from two cohorts (initial n = 36, ...

Breast cancer advancements include targeted therapies, oral medications for ER-positive/HER2-negative populations, and ...

A slow drug-release system has proven highly effective in treating certain bladder cancer patients whose tumors were previously unresponsive to therapy. A new targeted drug delivery system known as TA ...

MONTREAL, Nov. 13, 2025 /CNW/ - Myeloma Canada welcomes the Canadian Drug Agency's (CDA) two positive recommendations for the reimbursement of Blenrep (R) (belantamab mafodotin) -- a critical new ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of ...

High-titre convalescent plasma therapy given within a week of symptom onset reduced hospitalisation and death and was well tolerated in immunocompromised patients with mild COVID-19. This randomised ...